芒柄花黄素对人肾癌细胞786-O的抑制作用及机制研究

Abstract
Figure/Table
References (26)
Related Citation (15)

Download: PDF (825 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the inhibitory effect of formononetin on human renal carcinoma cell 786-O and its mechanism. Methods Human renal carcinoma cell 786-O cultured with different doses of formononetin. They were divided into control group (0 μmol/L, group A), formononetin low-dose group (20 μmol/L, group B), formononetin medium-dose group (40 μmol/L, group C), and formononetin high-dose group (80 μmol/L, group D) according to drug dose. CCK8 method was used to detect the proliferation of four group; apoptosis was detected by flow cytometry and Hoechst staining; the expression of miR-155 was detected by RT-PCR; the protein expressions of P-PI3K and P-AKT were detected by Western blot. Results After 72 h of culture, the inhibitory rate of cell proliferation in groups B, C and D were higher than those in 24 and 48 h of culture. After 48 h of culture, the inhibitory rate of cell proliferation in groups B, C and D were higher than those in 24 h of culture, and the differences were statistically significant (all P < 0.05). After 24, 48 and 72 h of culture, the inhibitory rate of cell proliferation in groups B, C and D were higher than those in group A; groups C and D were higher than that in group B; and group D was higher than that in group C, and the differences were statistically significant (all P < 0.05). The apoptosis rate of four groups were statistically significant (P < 0.05). In group B, C and D, cell shrinkage and nucleus were observed， and the higher the drug dose was, the more obvious the cell apoptosis was; the nucleus of group A was complete and full in morphology. The expression of miR-155 level and P-PI3K and P-AKT proteins levels in groups B, C and D were lower than those in group A, the expression miR-155 level and P-PI3K and P-AKT proteins levels in groups C and D were lower than those in group B, and the expression miR-155 level and P-PI3K and P-AKT proteins levels in group D was lower than that in group C, and the differences were statistically significant (all P < 0.05). Conclusion Formononetin can significantly inhibit proliferation and induce apoptosis in human renal carcinoma cell 786-O, and the mechanism may be related to the down-regulation of miR-155 expression to inhibit the activation of PI3K/AKT signaling pathway.

Key words： Formononetin 786-O Apoptosis miR-155 PI3K/AKT

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHEN Qing1 LI Haihong2 OU Weining1 ZHANG Xing3

Cite this article:

CHEN Qing1 LI Haihong2 OU Weining1 ZHANG Xing3. Study of inhibitory effect of formononetin on human renal carcinoma cell 786-O and its mechanism[J]. 中国医药导报, 2021, 18(12): 11-15,19.

URL:

https://www.yiyaodaobao.com.cn/EN/ OR https://www.yiyaodaobao.com.cn/EN/Y2021/V18/I12/11

[1] Li X，Yin A，Zhang W，et al. Jam3 Promotes Migration and Suppresses Apoptosis of Renal Carcinoma Cell Lines [J]. Int J Mol Med，2018，42（5）：2923-2929.
[2] Capitanio U，Montorsi F. Renal cancer [J]. Lancet，2016， 387（10021）：894-906.
[3] Yao JN，Zhang XX，Zhang YZ，et al. Discovery and anticancer evaluation of a formononetin derivative against gastric cancer SGC7901 cells [J]. Invest New Drugs，2019， 37（6）：1300-1308.
[4] Zhang J，Liu LK，Wang J，et al. Formononetin，an isoflavone from Astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells[J]. J Ethnopharmacol，2018，221：91-99.
[5] 柳青，梁梅花，张幸，等.芒柄花黄素对人膀胱癌细胞T739增殖、凋亡的影响及机制探讨[J].中国医药导报，2017，14（25）：4-7.
[6] Sánchez-Gastaldo A，Kempf E，Alba AG，et al. Systemic treatment of renal cell cancer：A comprehensive review [J]. Cancer Treat Rev，2017，60：77-89.
[7] Bacolod MD，Barany F，Pilones K，et al. Chapter Four-Pathways-and epigenetic-based assessment of relative immune infiltration in various types of solid tumors [J]. Adv Cancer Res，2019，142：107-143.
[8] Wang D，Xiao ZJ，Shou JZ，et al. Clinical analysis of 8 cases of the mixed epithelial and stromal tumour family of kidney [J]. Zhonghua Yi Xue Za Zhi，2019，99（10）：771-774.
[9] Park S，Bazer FW，Lim W，et al. The O-methylated isoflavone，formononetin，inhibits human ovarian cancer cell proliferation by sub G0/G1 cell phase arrest through PI3K/AKT and ERK1/2 inactivation [J]. J Cell Biochem，2018，119（9）：7377-7387.
[10] Xin M，Wang Y，Ren Q，et al. Formononetin and metformin act synergistically to inhibit growth of MCF-7 breast cancer cells in vitro [J]. Biomed Pharmacother，2019，109：2084-2089.
[11] Tay KC，Tan LT，Chan CK，et al. Formononetin: A Review of Its Anticancer Potentials and Mechanisms [J]. Front Pharmacol，2019，10：820.
[12] Zhang K，Wang YW，Wang YY，et al. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling [J]. Gene，2017，619：10-20.
[13] Dudics S，Venkatesha SH，Moudgil KD. The micro-RNA expression profiles of autoimmune arthritis reveal novel biomarkers of the disease and therapeutic response [J]. Int J Mol Sci，2018，19（18）：2293.
[14] McGeary SE，Lin KS，Shi CY，et al. The biochemical basis of microRNA targeting efficacy [J]. Science，2019， 366（6472）：eaav1741.
[15] Dragomir MP，Knutsen E，Calin GA. SnapShot：Unconventional miRNA Functions [J]. Cell，2018，174（4）：1038-1038.e1.
[16] Shahid S，Kim G，Johnson NR，et al. MicroRNAs from the parasitic plant Guscuta campestris target host messenger RNAs [J]. Nature，2018，553（7686）：82-85.
[17] Hines PJ. MicroRNAs in functional and dysfunctional pain [J]. Science，2017，356（6343）：1134-1136.
[18] Sambandan S，Akbalik G，Kochen L，et al. Activity-dependent spatially localized miRNA maturation in neuronal dendrites [J]. Science，2017，355（6325）：634-637.
[19] Cao H，Huang S，Liu A，et al. Up-regulated expression of miR-155 in human colonic cancer [J]. J Cancer Res Ther，2018，14（3）：604-607.
[20] Chen L，Yang X，Zhao J，et al. Circ_0008532 promotes bladder cancer progression by regulation of the miR-155-5p/miR-330-5p/MTGR1 axis [J]. J Exp Clin Cancer Res，2020，39（1）：94.
[21] Shao C，Yang F，Qin Z，et al. The value of miR-155 as a biomarker for the diagnosis and prognosis of lung cancer：a systematic review with meta-analysis [J]. BMC Cancer，2019，19（1）：1103.
[22] Santos JC，Lima NDS，Sarian LO，et al. Exosome-mediated breast cancer chemoresistance via miR-155 transfer [J]. Sci Rep，2018，8（1）：829.
[23] Tao M，Zhou Y，Jin Y，et al. Blocking lncRNA MIR155HG/miR-155-5p/-3p inhibits proliferation，invasion and migration of clear cell renal cell carcinoma [J]. Pathol Res Pract，2020，216（2）：152803.
[24] Yan Y，Huang H. Interplay Among PI3K/AKT，PTEN/FOXO and AR Signaling in Prostate Cancer [J]. Adv Exp Med Biol，2019，1210：319-331.
[25] Costa RLB，Han HS，Gradishar WJ. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer：A review [J]. Breast Cancer Res Treat，2018，169（3）：397-406.
[26] Han B，Wang S，Zhao H. MicroRNA-21 and microRNA-155 Promote the Progression of Burkitt’s Lymphoma by the PI3K/AKT Signaling Pathway [J]. Int J Clin Exp Pathol，2020，13（1）：89-98.